External innovation holds the key for long-term growth
03/12/20 -"Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of Cabometyx, Onivyde, Palovarotene, Decapeptyl and Dysport ..."
Pages
55
Language
English
Published on
03/12/20
You may also be interested by these reports :
17/09/26
Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen’s near- and mid-term risks. ...
15/09/26
At a time when Novartis and AstraZeneca nurse a run of late-stage R&D setbacks, GSK’s recent clinical trial successes for oncology candidates, ...
14/09/26
Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled ...
11/09/26
The recent R&D setbacks in cardiovascular and neuroscience areas have prompted us to revise our target price downwards. In the process, we have also ...